Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin
Patients with a history of hypersensitivity reactions to prior chemotherapy administered for previous cancer diagnoses are eligible to participate in the study, unless the hypersensitivity reaction consisted of anaphylaxis not amenable to desensitization
Patients with a history of hypersensitivity to nickel
Patients with history of hypersensitivity to liposomal products
Subjects with a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins; or a history of prior acute hepatotoxicity attributable to phenytoin.
Has a history of vasculitis.
No history of severe hypersensitivity reaction to Cremophor EL
History of severe hypersensitivity reactions to cisplatin or vinblastine or other products of the same class;
Has a history of vasculitis.
History of hypersensitivity to sertraline
Any history of hypersensitivity to irinotecan
History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction.
Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination
History of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effects
History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics or opioids.
History of clinical hypersensitivity to the immunotherapy proposed for combination treatment.
A history of sun hypersensitivity or photosensitive dermatitis.
History of infusion-related reactions and/or hypersensitivity to trastuzumab, (ado-)trastuzumab emtansine;
History of hypersensitivity to thyrotropin alpha (Thyrogen)
History of severe hypersensitivity reaction to Cremaphor EL
Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
Patients who have a history of ataxia telangiectasia or other documented history of radiation hypersensitivity
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor, or history of hypersensitivity type reaction to polysorbate  or other components of the formulation of Oraxol
History of hypersensitivity to cyclophosphamide, fludarabine or IL-.
Patients with a history of hypersensitivity to bosutinib or axitinib
History of hypersensitivity to any of the kinase inhibitors included in this study
History of hypersensitivity to hydrogel.
History of
Subjects with history of hypersensitivity to azoles
History of hypersensitivity to vemurafenib
Patients with history of hypersensitivity to conductive hydrogel are not eligible
Have a history of hypersensitivity to dacarbazine (DTIC)
History or presence of hypersensitivity or idiosyncratic reaction to deferiprone or deferoxamine;
History of hypersensitivity to a taxane
History of hypersensitivity to cyclophosphamide, fludarabine or IL-
The subject has a history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine (DTIC)
History of hypersensitivity to dacarbazine
A history of ataxia telangiectasia or other documented history of radiation hypersensitivity
History of:
History of prior grade  or  hypersensitivity or any toxicity to trastuzumab that warranted permanent cessation of this antibody
Subject has a history of hypersensitivity to porcine derived gelatin or collagen.
Subject has a history of hypersensitivity to microbial Transglutaminase.
Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema or anaphylaxis) to axitinib or sunitinib.
Current or past history of severe hypersensitivity to any other antibody products
History of severe hypersensitivity reaction to taxanes
History of hypersensitivity to anakinra.
History of hypersensitivity to denosumab.
History of hypersensitivity to everolimus.
History of hypersensitivity to castor oil
History of hypersensitivity to ibrutinib
History of hypersensitivity to TPIV
History of
Known history of cardiomyopathy
History of prior >= G  hypersensitivity (HSR) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agent
History of severe hypersensitivity reaction (>= grade ) to docetaxel
Patients with a history of grade >=  hypersensitivity reaction to trastuzumab, OR grade >=  with the most recent trastuzumab infusion before study entry, OR continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions are not eligible for participation
History of hypersensitivity to any compound in the tetracycline antibiotics group
History of hypersensitivity to ipilimumab
Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
A history of ataxia telangiectasia or other documented history of radiation hypersensitivity
History of hypersensitivity to sirolimus
History of hypersensitivity to vorinostat
History of hypersensitivity to hydroxychloroquine
Any history of adverse reaction or hypersensitivity to LDAC
History of hypersensitivity to -aminoquinoline compound
A history of a severe hypersensitivity reaction to ipilimumab or dabrafenib
History of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis)
History of hypersensitivity to hydrogel
Prior history of cardiomyopathy.
History of hypersensitivity to amikacin or other aminoglycosides
History of hypersensitivity to taxanes or drug formulations containing Cremophor.
Patients with a history of D mutations
History of:
History of hypersensitivity reactions attributed to simvastatin
History of severe hypersensitivity reaction to capecitabine, -FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)
History of hypersensitivity to other psychostimulants
Has a history of severe hypersensitivity reaction to pembrolizumab, Cisplatin or radiotherapy or their analogs
History hypersensitivity to opioids.
History of hypersensitivity or reaction to N-methyl-D-aspartate (NMDA) receptor antagonists
Patient has a history of hypersensitivity to fentanyl or opioids
PATIENTS: History of hypersensitivity to haloperidol or chlorpromazine
History of hypersensitivity to pregabalin or gabapentin
Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible
History of hypersensitivity to all of the following antibiotics: penicillin, erythromycin, clindamycin, and any fluoroquinolone
History of hypersensitivity to haloperidol or benzodiazepine
Prior history of acupressure use
No history of severe hypersensitivity reactions to drugs or other causes (e.g., beestings)
History of phenylketonuria (PKU)
Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of hypersensitivity to previous influenza vaccination or severe or moderate hypersensitivity to eggs/egg protein
History of hypersensitivity or idiosyncratic reactions to azoles
History of hypersensitivity reaction to Xolair or any ingredient of Xolair
History of hypersensitivity to taxanes; hypersensitivity to the solvent does not preclude patient participation in this Study
History of hypersensitivity or unexpected reactions to capecitabine, other fluoropyrimidine agents, or any of their ingredients
History of relapse of ALL
History of hypersensitivity to nickel
History of iritis or episcleritis.
The patient received omacetaxine or has a history of hypersensitivity.
Patients with a history of hypersensitivity to nickel.
History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor
